- New 38-gene testing panel and clinical decision
support tool analyzes a patient's genetics and co-medications for
their impact on drug and dose personalization -
SAN
FRANCISCO, May 19, 2022 /PRNewswire/ -- Invitae
(NYSE: NVTA), a leading medical genetics company, today announced
the commercial availability of the expanded Invitae
Pharmacogenomics (PGx) Panel which includes the specialized Invitae
Pharmacogenomics Mental Health Panel and access to a clinical
decision support tool (CDST). With this launch, Invitae now has one
of the most comprehensive commercially available PGx panels in the
industry. In addition to mental health medications, the panel
aligns with PGx-specific guidelines and published evidence that
affects hundreds of commonly used medications, including frequently
prescribed medications for high-risk patients in primary care,
cardiology, endocrinology, pain management and oncology.
Nearly one in four patients has been prescribed medications
for which they are predicted to have an atypical response due to
their genetics. Given the compelling evidence that patient care can
benefit from this information, PGx testing is poised to become the
standard of care across all medical prescribing, utilizing both
broad panels and specialized tests as available. However,
accomplishing the goal of integrating PGx into standard of care
requires more support for healthcare providers to recognize the
utility of PGx testing and implement it in their
practices.
Major progress is being made at the state and federal level to
remove barriers to adoption of PGx. Medicare local coverage
determinations (LCDs) have rolled across the country aligning PGx
testing coverage with the evidence. Congress also recently
introduced the Right Drug Dose Now Act, which, if passed, would
increase awareness of and access to PGx. States have also made
moves to encourage the use of pharmacogenetics in clinical care;
for example, legislation recently introduced in California is designed to align Medi-Cal
coverage for pharmacogenomics with Food and Drug Administration
(FDA) and Clinical Pharmacogenetics Implementation Consortium
(CPIC) evidence. With the tools to successfully utilize PGx,
providers can potentially reduce adverse drug effects, including
side effects and treatment failures, save time, reduce costs and
improve patient care.
Invitae Pharmacogenomics Panel
The Invitae
Pharmacogenomics Panel includes 38 genes, covering the genes and
variants affecting 98% of the medicines that according to CPIC and
FDA can lead to an actionable major or moderate drug-gene
interaction; this 98% figure does not include genes and variants
that are ordinarily tested for diagnosis of specific diseases but
may also impact drug therapy.
Furthermore, access to Invitae's CDST, YouScript, is included
with testing. YouScript is one of the most comprehensive medication
management analytics and clinical decision support software
offerings on the market employing over 17,000 curated references
and product inserts to simulate a team of clinical pharmacists
delivering real-time, evidence-based guidance. YouScript aids
providers in mitigating the risk of potential drug-gene and
drug-drug-gene interactions.
A recent study shows that using Invitae's YouScript
Precision Prescribing Software and PGx testing reduce
re-hospitalizations and emergency department visits by 52% and 42%
respectively saving an estimated $4,382 per patient in 60 days. Considering that
the U.S. spent an estimated $528
billion on non-optimized medications in 2016, exceeding the
cost of the drugs themselves or any major chronic disease, making
PGx testing and YouScript more widely available could result in
substantial care improvements and cost reductions.
"Ninety-nine percent of patients have genetic variants that can
impact medication response making pharmacogenomics a foundational
element for any precision medicine program," says Kristine Ashcraft, medical affairs director,
pharmacogenomics at Invitae. "At Invitae, we pride ourselves on
ease-of-use, so we offer both genetic testing and clinical decision
support to enable clinicians to easily benefit from genetic
insights when making prescription choices at the point of
care."
Invitae Pharmacogenomics Mental Health Panel
The
panel aligns with some payer coverage that limits the number of
genes covered for mental health. Psychiatrists and other doctors
have been increasingly using PGx testing in mental health treatment
because the majority of mental health medications have
evidence-based PGx guidance and utilization of PGx in their
patients has been shown to reduce the risk of side effects, lead to
more rapid stabilization with reduced medication switching, and
increase the chance that patients can successfully manage their
conditions. Non-personalized prescribing can have serious
consequences. One study found that patients with unrecognized
PGx variants significantly impacting response to es(citalopram)
were victims of suicide 34.3% more often than individuals without
variants affecting response to the drug.
"In the U.S. alone, over 20% of adults take five or more
medications every day and one of the most commonly prescribed drug
types is antidepressants," continues Ashcraft. "This trend
highlights the need to bring PGx testing into mainstream medical
care, making it the standard, especially when treating polypharmacy
patients and those with mental health conditions."
To learn more about Invitae's expanded PGx testing, visit
Invitae.com.
1 https://cpicpgx.org/genes-drugs/;
https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
2 https://cpicpgx.org/genes-drugs/
https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
3 https://www.futuremedicine.com/doi/10.2217/pme.15.47
4
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2735464
5
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540033/';
https://pubmed.ncbi.nlm.nih.gov/26086890/;
https://pubmed.ncbi.nlm.nih.gov/32045941/
6 U.S. Census Bureau (2017). 2017 national population
projection tables: Main series. Retrieved from
https://www.census.gov/data/tables/2017/demo/popproj/2017-summary-tables.html
About Invitae
Invitae Corporation (NYSE: NVTA) is a
leading medical genetics company, whose mission is to bring
comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people. Invitae's goal is to
aggregate the world's genetic tests into a single service with
higher quality, faster turnaround time and lower prices. For more
information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the availability, features and potential impact of the
company's products; the company's belief that PGx testing is poised
to become the standard of care across all medical prescribing; the
company's beliefs regarding legislative progress to remove barriers
to the adoption of PGx; and the potential benefits of PGx testing.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: the company's history of losses; the company's ability
to compete; the company's failure to manage growth effectively; the
company's need to scale its infrastructure in advance of demand for
its tests and to increase demand for its tests; the company's
ability to use rapidly changing genetic data to interpret test
results accurately and consistently; security breaches, loss of
data and other disruptions; laws and regulations applicable to the
company's business; and the other risks set forth in the company's
filings with the Securities and Exchange Commission, including the
risks set forth in the company's Quarterly Report on Form 10-Q for
the quarter ended March 31, 2022.
These forward-looking statements speak only as of the date hereof,
and Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Contact:
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-launches-expanded-pharmacogenomics-panel-and-specialized-mental-health-panel-301550727.html
SOURCE Invitae Corporation